Featured Content

The CenterWatch Monthly Industry Close-Up

Friday, September 1, 2017

In 2017, 13% of cancer diagnosed in adults will be rare cancers. Of those, prostate cancer repre­sents 9.6% in the U.S. Prostate cancer is the second most common cancer and the second lead­ing cause of cancer-related death in men in the U.S. According to the National Center for Health Statistics, approximately $11.9 billion is spent each year in the U.S. on prostate cancer treatment.

[Read More]

Designing outcomes that matter to patients

Tuesday, August 1, 2017

Even as the pharmaceutical industry shifts to a more patient-centric model for clinical trials, many enthusiastic R&D teams struggle to get started. How can you engage real patients to improve clinical trial design and drive better results?

[Read More]

Research champions—Not your grandmother’s referring physicians

Tuesday, August 1, 2017

The changing ecosystem of clinical research—empowered by advances ranging from CRISPR Cas9 technology and genomic analysis of biomarkers to mechanobiology and predictive data monitor—calls us to reconsider the role of referring physicians in patient enrollment. These and other technologies will shift resources from the traditional investigative site model focused on a large number of sites enrolling many patients to a more networked model of sub-investigators focused on screening patients for specific biomarkers. 

[Read More]

Embrace payment technology to improve processes

Tuesday, August 1, 2017

In today’s technology-enabled world, consumers expect instant gratification, especially when it comes to payments. The clinical trial industry, which historically has been slow to embrace new technologies, must recognize that it needs to adopt new payment technologies to continue to attract patients for clinical trials. The benefits that payment automation solutions can deliver to trials, such as increased patient retention rates and enhanced patient engagement, as well as streamlined internal processes, have never been more important.

[Read More]

The CenterWatch Monthly Industry Snapshot, July 2017

Monday, July 3, 2017

Healthcare stakeholders recognize that there is a clear, ethical rationale to support patient engagement in clinical trials. Setting standards that describe how patient engagement is achieved will lead to research findings that are more pertinent to patients’ concerns and dilemmas.1 However, as there are limited comparative analytic studies to recommend a particular method that improves understanding of patients’ concerns and enables comparisons of the methods employed, it is unclear how to best engage patients and how to measure the success of engagement.

[Read More]

Standard data, extraordinary innovations in clinical trials

Saturday, July 1, 2017

As clinical trials require more robust and user-friendly systems to monitor data and conduct effective risk-based monitoring, the use of industry data standards can greatly drive efficiencies and reduce variations in data format from one study to the next. The increasingly wide acceptance of Clinical Data Interchange Standards Consortium (CDISC) standards, and subsequent requirement of the CDISC Study Data Tabulation Model (SDTM) standards , has opened innovation opportunities within the industry.

[Read More]

Pharmacovigilance in the Russian Federation

Thursday, June 15, 2017

In the Russian Federation, two codes of rules for pharmacovigilance are presently used. The local regulatory body responsible for pharmacovigilance is the Federal Service for Surveillance in Healthcare (RosZdravNadzor) and the Federal State Budgetary Institution named the Centre for Monitoring and Clinical Economic Expertise under the RosZdravNadzor.

[Read More]